Earnings Summary

Halozyme Therapeutics, Inc.’s revenue jumped 386.02% since last year same period to $189.56Mn in the Q4 2017. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 197.44% jump in its revenue since last 3-months.

Halozyme Therapeutics, Inc.’s net profit jumped 552.36% since last year same period to $123.88Mn in the Q4 2017. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 4406.44% jump in its net profits since last 3-months.

Halozyme Therapeutics, Inc.’s net profit margin jumped 193.07% since last year same period to 65.35% in the Q4 2017. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 1415.05% jump in its net profit margins since last 3-months.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.47 - a -7.84% fall from last quarter’s estimates.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 0.47.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Halozyme Therapeutics, Inc.’s return on assets (ROA) stands at 0.12.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Halozyme Therapeutics, Inc.’s return on equity (ROE) stands at 1.1.